Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CINC

CinCor Pharma (CINC) Stock Price, News & Analysis

CinCor Pharma logo

About CinCor Pharma Stock (NASDAQ:CINC)

Key Stats

Today's Range
$29.02
$29.35
50-Day Range
$28.73
$29.56
52-Week Range
$10.53
$43.15
Volume
6.35 million shs
Average Volume
818,447 shs
Market Capitalization
$1.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.

Receive CINC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CinCor Pharma and its competitors with MarketBeat's FREE daily newsletter.

CINC Stock News Headlines

Why I'm telling friends to avoid gold stocks
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
CinCor Pharma Inc.
Impel Pharmaceuticals hit by another C-suite departure
See More Headlines

CINC Stock Analysis - Frequently Asked Questions

CinCor Pharma (CINC) raised $176 million in an initial public offering on the week of November 7th 2022. The company issued 11,000,000 shares at $15.00-$17.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that CinCor Pharma investors own include ARMOUR Residential REIT (ARR), AstraZeneca (AZN), AGNC Investment (AGNC), Amgen (AMGN), Broadcom (AVGO), Costco Wholesale (COST) and Cisco Systems (CSCO).

Company Calendar

Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CINC
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

Net Income
$-50,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.74) per share

Miscellaneous

Free Float
36,937,000
Market Cap
$1.27 billion
Optionable
Not Optionable
Beta
N/A
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:CINC) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners